Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Felipe Cardenal, M.P. López-Cabrerizo, Antonio Antón et al. · Journal of Clinical Oncology · 1999
PURPOSE: We conducted a randomized trial to compare gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The primary end point of the comparison was response rate. PATIENTS AND METHODS: A total of 135 chemotherapy-naive patients with advanced NSCLC were randomized to receive either gemcitabine 1,250 mg/m2 intravenously (IV) days 1 and 8 or etoposide 100 mg/m2 IV days 1 to 3 along with cisplatin 100 mg/m2 IV day 1. Both treatments were administered in 21-day cycles. One hundred thirty-three patients were included in the intent-to-treat analysis of response. RESULTS: The response rate (externally validated) for patients given gemcitabine-cisplatin was superior to that for patients given etoposide-cisplatin (40.6% v 21.9%; P = .02). This superior response rate was associated with a significant delay in time to disease progression (6.9 months v 4.3 months; P = .01) without an impairment in quality of life (QOL). There was no statistically significant difference in survival time between both arms (8.7 months for gemcitabine-cisplatin v 7.2 months for etoposide-cisplatin; P = .18). The overall toxicity profile for both combinations of drugs was similar. Nausea and vomiting were reported more frequently in the gemcitabine arm than in the etoposide arm. However, the difference was not significant. Gemcitabine-cisplatin produced less grade 3 alopecia (13% v 51%) and less grade 4 neutropenia (28% v 56% ) but more grade 3 and 4 thrombocytopenia (56% v 13%) than did etoposide-cisplatin. However, there were no thrombocytopenia-related complications in the gemcitabine arm. CONCLUSION: Compared with etoposide-cisplatin, gemcitabine-cisplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC.
Cited by 471 works. doi:10.1200/jco.1999.17.1.12
Authors
- Felipe Cardenal
- M.P. López-Cabrerizo
- Antonio Antón
- Vicente Alberola
- Bartomeu Massutí
- Alfredo Carrato
- I. Barneto
- María Lomas
- Margarita García
- PILAR LIANES
- Joaquín Montalar
- Catalina Vadell
- J.L. González-Larriba
- Binh Nguyen
- Angel Artal
- Rafael Rosell
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
- Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
- Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
- ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME